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T slating evidence-based treatments into clinicalactice is fundamental to modern health carelivery. Yet numerous studies demonstrate lim-
 of guideline-endorsed treatment recommen-
dations.1,2 Why is this so? There are many possible
explanations. Patient characteristics such as age, comor-
bidity, socioeconomic status, cultural background and
frailty are likely to be important. Most trials of novel drugs
or devices are funded by industry. Trials are very expensive,
and a trial sponsor is understandably keen to ensure that
their product is administered to those patients most likely
to benefit. Consequently, patients entered into clinical
trials are typically younger and have less comorbidity than
the broader population of patients with a particular condi-
tion. This was found to be the case in a recent Canadian
registry report on patients admitted with acute coronary
syndrome (ACS), which compared the baseline character-
istics of those who were included in clinical trials with the
much larger cohort of patients who were not.3 Other
variables also limit the translation of evidence-based treat-
ments. For ACS, which requires acute hospital care, the
type of hospital (eg, peripheral versus major teaching
hospital) and its location (eg, urban versus rural or remote
setting) can determine the level of medical expertise and
complexity of treatment offered to a patient.
How best then to identify all the factors that limit the
translation of evidence-based medicine into clinical prac-
tice? One approach is to take a “snapshot” of all patients
with an acute condition admitted to every hospital nation-
wide and to compare patient characteristics, patterns of
investigation, treatment and patient outcomes. This would
allow hospitals, states and even countries to be compared,
if the snapshot is broad enough. Undertaking such a study
is logistically daunting, but in a landmark study published
in this issue of the Journal, Chew and colleagues have
attempted exactly that.4 The investigators approached 525
hospitals across Australia and New Zealand and obtained
ethics approval from 478 to perform a prospective audit of
patients admitted with suspected or confirmed ACS during
2 weeks in May 2012. They enrolled 4398 patients in 286
nrol patients were
ith ACS during the
HOT ACS study are
pt-out consent pro-
) no doubt contrib-
econd, standardised
 collection ensured
consistency between participating hospitals, in contrast to
other methods of administrative data extraction where
data validity is often questioned.6 Third, including a survey
to document the range of cardiac services at the participat-
ing hospitals facilitated benchmarking between institu-
tions. Facilities for percutaneous coronary intervention and
coronary artery bypass surgery were available in less than
30% and 20% of hospitals, respectively. This expected
finding probably explains the high rate of interhospital
transfer, involving 26% of enrolled patients. However,
surprisingly, only two-thirds of the 286 hospitals in the
study contained an acute coronary care ward.
The SNAPSHOT ACS study is in every sense a contem-
porary “real world” audit of the diagnostic evaluation and
management of ACS across Australasia. The authors
report some noteworthy findings. Although virtually all
patients presented to a hospital that was capable of provid-
ing acute reperfusion therapy for ST-segment-elevation
myocardial infarction, this was administered to only two-
thirds of patients with this diagnosis. In addition, patients
with higher Global Registry of Acute Coronary Events
(GRACE) scores (and higher risk of hospital mortality)
were less likely to receive an invasive management strat-
egy. Previous publications from large prospective registries
have reported similar findings.7,8 This may be explained by
factors such as advanced age and renal failure, which
contribute to the GRACE score but also reduce the likeli-
hood of acute intervention.3 Other major comorbidities are
also likely to contribute to underuse of evidence-based
therapies in these high-risk patients.7 These and other
findings deserve further published analysis of this unique
dataset.
Most disturbing are the substantial variations found in
implementation of evidence-based management and in
patient outcomes, not only between hospitals but also
between jurisdictions. Differences in the use of invasive
diagnostic and therapeutic measures (coronary angio-
graphy and percutaneous or surgical revascularisation) are
to be expected, as most enrolled hospitals lacked these
facilities.4 On the other hand, the significant differences
between hospitals in the use of guideline-recommended
medications, cardiac rehabilitation, and diet and exercise
advice are harder to explain. An important feature of the
SNAPSHOT ACS study is the benchmarking of (de-identi-
fied) hospital data to enable individual clinicians and
institutions to compare their performance against other
institutions providing comparable services. But bench-
marking needs to be followed by change-management
strategies to improve the uptake of evidence-based treat-
ments in underperforming hospitals.
Jurisdictional differences in use of evidence-based thera-
pies for ACS and patient outcomes indicate differences in
health service policy, resourcing and delivery. Exploring
these differences will be important to identify jurisdictional147MJA 199 (3) · 5 August 2013
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MJA 199 (148barriers to implementing evidence-based treatments and
will require bringing together national and state govern-
ment agencies, professional bodies, individual clinicians
and researchers across all hospitals. This approach has
been applied successfully (albeit on a limited scale) in the
management of ACS, acute heart failure and stroke.9,10
However, a clear message from the SNAPSHOT ACS
study is that much broader engagement of these stake-
holders will be required to improve the outcomes of
patients with ACS across the entire health sector.
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